Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pargluva Panic: Need For Additional Trial Prompts Merck To Drop Partnership

Executive Summary

Bristol-Myers Squibb remains in discussions with FDA about what clinical studies would be required to address concerns about the cardiovascular safety profile of its type 2 diabetes treatment candidate Pargluva (muraglitazar)
Advertisement

Related Content

Bristol/Astra Diabetes Deal Further Indicates Bristol Will Stay Independent
Advisory Panels, Not FDA, Are Most Affected By Rx Safety Concerns – Gottlieb
Bristol Vanlev Settlement Does Not Include Pre-Marketing Results Disclosure
Pfizer’s Product Parachute? Firm Could See Rally Around New Approvals
Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says
Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink
Rx Industry May Need To Inject More Funds Into R&D – GSK Exec
Pargluva Effect: Bristol Foresees More Independent Scrutiny Of Trial Data
AstraZeneca Galida NDA Delayed Until 2007 Due To PPAR Safety Concerns
AstraZeneca Galida NDA Delayed Until 2007 Due To PPAR Safety Concerns

Topics

Advertisement
UsernamePublicRestriction

Register

PS046494

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel